The endothelin axis as therapeutic target in human malignancies: Present and future

Current Pharmaceutical Design

Volumn 18, Issue 19, 2012, Pages 2720-2733

  Bagnato, Anna ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cancer therapy; Chemoresistance; Endothelin; Endothelin receptor; Epithelial mesenchymal transition; arrestin

Indexed keywords

AFLIBERCEPT; ATRASENTAN; BETA ARRESTIN; BETA CATENIN; BOSENTAN; CISPLATIN; COLLAGENASE 3; CYCLOOXYGENASE 2; ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENZYME PRECURSOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; G PROTEIN COUPLED RECEPTOR; GEFITINIB; GELATINASE A; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE; NEBENTAN; PACLITAXEL; PLATINUM; STROMELYSIN; TAXANE DERIVATIVE; UNINDEXED DRUG; UVOMORULIN; ZIBOTENTAN;

ANALGESIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BONE DEVELOPMENT; BONE METASTASIS; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENESIS; CELL ACTIVITY; CELL COMMUNICATION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CLINICAL TRIAL (TOPIC); COLON CANCER; DNA SYNTHESIS; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; ENDOMETRIUM CANCER; ENDOTHELIN AXIS; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOMODULATION; INTRACELLULAR SIGNALING; KAPOSI SARCOMA; LUNG CANCER; LYMPHANGIOGENESIS; MELANOMA; MELANOMA CELL; MITOGENICITY; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NASOPHARYNX CARCINOMA; NEOPLASM; NEUROBLASTOMA; NONHUMAN; OSTEOBLASTOMA; OSTEOSARCOMA; OVARY CANCER; PATHOPHYSIOLOGY; PHENOTYPE; PLEIOTROPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REVIEW; TRANSACTIVATION; TREATMENT DURATION; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CARCINOMA; WART VIRUS;

EID: 84862563639     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212800626157     Document Type: Review

References (134)

1. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003; 3: 110-6.
2. Bagnato A, Catt KJ. Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998; 9: 378-83.
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
4. Bagnato A, Spinella F, Rosanò L. The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. Can J Physiol Pharmacol 2008; 86: 473-84.
5. Levin ER. Endothelins. N Engl J Med 1995; 333: 356-63.
6. Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol 2000; 35: S3-5.
7. Rozengurt E. Mitogenic signalling pathways induced by G proteincoupled receptors. J Cell Physiol 2007; 213: 589-02.
8. Bagnato A, Tecce R, Moretti C, Di Castro V, Spergel D, Catt KJ. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cell. Clin Cancer Res 1995; 1: 1059-66.
9. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis unduced by colon cancer cells. Cell 1998; 93: 705-16.
10. Del Bufalo D, Di Castro V, Biroccio A. Endothelin-1 acts as a survival factor in ovarian carcinoma cells. Clin Sci (Lond) 2002; 48: 302S-5S.
11. Defea K. Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br J Pharmacol 2008; 1: S298-S309.
12. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002; 115: 455-65.
13. Vacca F, Bagnato A, Catt KJ, Tecce R. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000; 60: 5310-7.
14. Barki-Harrington L, Rockman HA. Beta-arrestins: multifunctional cellular mediators. Physiology 2008; 23: 17-22.
15. Rosanò L, Di Castro V, Spinella F, et al. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity. Cancer Res 2007; 67: 6351-9.
16. Del Bufalo D, Di Castro V, Biroccio A, et al. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. Mol Pharmacol 2002; 61: 524-32.
17. Bagnato A, Birilli A, Salani D, et al. Growth inhibition of cervix carcinoma cell in vivo by endothelin A receptor blockade. Cancer Res 2002; 62: 6381-4.
18. Rosanò L, Di Castro V, Spinella F, Nicotra MR, Natali PG, Bagnato A. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo. Mol Cancer Ther 2007; 6: 2003-11.
19. Akhavan A, McHugh KH, Guruli G, et al. Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia 2006; 8: 725-32.
20. Salani D, Taraboletti G, Rosanò L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelia cells and stimulates neovascularization in vivo. Am J Pathol 2000; 157: 1703-11.
21. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin- 1 induces vascular endothelial growth factor by increasing hypoxia-inducibile factor-1α in ovarian carcinoma cells. J Biol Chem 2002; 277: 27850-5.
22. Bagnato A, Spinella F. Emerging role of endothelin-1 in tumor angiogenesis. Trends Endocrinol Metab 2003; 14: 44-50.
23. Spinella F, Rosanò L, Del Duca M, et al. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor- 1alpha in melanoma cells. Plos One 2010; 5(6) e11241
24. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin Cancer Res 2004; 10: 4670-79.
25. Spinella F, Rosanò L, Di Castro V, et al. Endothelin-1 and endothelin- 3 promote invasive behavior via hypoxia-inducible factor-1α in human melanoma cells. Cancer Res 2007; 67: 1725-34.
26. Wülfing P, Diallo R, Kersting C, et al. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term followup. Clin Cancer Res 2003; 9: 4125-31.
27. Spinella F, Caprara V, Garrafa E, et al. Endothelin axis induces metalloproteinase activation and invasiveness in human lymphatic endothelial cells. Can J Physiol Pharmacol 2010; 88: 782-7.
28. Spinella F, Garrafa E, Di Castro V, et al. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 2009; 69: 2669-76.
29. Clasper S, Royston D, Baban D, et al. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res 2008; 68: 7293-03.
30. Rosanò L, Varmi M, Salani D, et al. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 2001; 61: 8340-6.
31. Rosanò L, Spinella F, Salani D, et al. Therapeutic targeting of the endothelin A receptor in human ovarian carcinoma. Cancer Res 2003; 63: 2447-53.
32. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med. 2004; 2:16.
33. Rosanò L, Spinella F, Di Castro V, et al. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma. Mol Cancer Ther 2006; 5: 833-42.
34. Hannigan G, Troussard AA, Dedhar S. Integrin-linked kinase: a cancer therapeutic target inique among its ILK. Nat Rev Cancer 2005; 5: 51-63.
35. Umhauer S, Ruch RJ, Fanning J. Gap junctional intercellular communication and connexin 43 expression in ovarian carcinoma. Am J Obstet Gynecol 2000; 182: 999-000.
36. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells. J Biol Chem 2003; 278: 41294-301.
37. Thiery JP. Epithelial-mesenchimal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-54.
38. Peinado H, Olmeda D, Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-28.
39. Bagnato A, Rosanò L. Epithelial-mesenchymal transition in ovarian cancer progression: a crucial role for the endothelin axis. Cell Tissues Organs 2007; 185: 85-94.
40. Rosanò L, Spinella F, Di Castro V, et al. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells. Cancer Res 2005; 65: 11649-57.
41. Rosanò L, Spinella F, Di Castro V, et al. Endothelin-1 is required during epithelial to mesenchymal transition in ovarian cancer progression. Exp Biol Med (Maywood) 2006; 231: 1128-31.
42. Gavert N, Ben-Ze'ev A. β-Catenin signalling in biological control and cancer. J Cell Biochem 2007; 102: 820-8.
43. Rosanò L, Bagnato A. Convergent pathways link the endothelin A receptor to the beta-catenin: the beta-arrestin connection. Cell Cycle 2009; 8: 1462-3.
44. Rosanò L, Cianfrocca R, Masi S, et al. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 2009;106: 2806-11.
45. Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A. beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. Can J Physiol Pharmacol 2010; 88: 796-01.
46. Wang Z, Li Y, Ahmad A, et al. Pancreatic cancer: understanding and overcoming chemresistance. Nat Rev Gastroenterol Hepatol 2011; 8: 27-33.
47. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-73.
48. Jazaeri AA, Awtrey CS, Chandramouli GV, et al. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res 2005; 11: 6300-10.
49. Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 2007; 31: 277-83.
50. Helleman J, Smid M, Jansen MP, van der Burg ME, Beins EM. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture. Gynecol Oncol 2010: 117: 170-6.
51. Rosanò L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 2011; 17: 2350-60.
52. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
53. Berry NB, Bapat SA. Ovarian cancer plasticity and epigenomics in the acquisition of a stem-like phenotype. J Ovarian Res 2008; 1: 8.
54. Ahmed N, Abubaker K, Findlay J, Quinn M. Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010; 10: 268-78.
55. Yin G, Chen R, Alvero AB, et al. TWISTing stemness, inflammation, and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 2010; 29: 3545-53.
56. Guise TA, Mohammad KS, Clines G, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006; 12: 6213s-6s.
57. Yin JJ, Mohammed KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastasis. Proc Natl Acad Sci USA 2003; 100: 10954-9.
58. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s-00s. javascript:popRefLink(8,'rg20','17062717')
59. Khodorova A, Navarro B, Jovaville LS, et al. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury. Nat Med 2003; 9: 1055-1061.
60. Davar G. Endothelin-1 and metastatic cancer pain. Pain Med 2001; 2: 24-7.
61. Hans G, Deseure K, Adriaensen H. Endothelin-1-induced pain and hyperalgesia: a review of pathophysiology, clinical manifestations and future therapeutic options. Neuropeptides 2008; 42: 119-32.
62. Grimshaw MJ. Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 2007; 14: 233-244.
63. Kandalaft LE, Motz GT, Duraiswamy J, Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011; 30: 141-51.
64. Kandalaft LE, Facciabene A, Buckanovich RJ, Coukos G. Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009; 15: 4521-8.
65. Buckanovich RJ, Facciabene A, Kim S, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14: 28-36.
66. Donninger H, Bonome T, Radonovich M, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene 2004; 23: 8065-77.
67. Kajiyama H, Shibata K, Terauchi M, et al. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin. Cancer Res 2005; 11: 1798-08.
68. Kopetz ES, Nelson JB, Carducci MA. Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs 2002; 20: 173-82.
69. Venuti A, Salani D, Manni V, Poggiali F, Bagnato A. Expression of endothelin-1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy. FASEB J 2000; 14: 2277-83. javascript:popRefLink(8,'rg-27','15361855')
70. Smollich M, Wulfing P. The endothelin axis: a novel target for pharmacotherapy of female malignancies. Curr Vasc Pharmacol 2007; 5: 239-48.
71. Grimshaw MJ, Hagemann T, Ayhan A, Gillett CE, Binder C, Balkwill FR. A role for endothelin-2 and its receptors in breast tumor cell invasion. Cancer Res 2004; 64: 2461-8.
72. Hagemann T, Binder C, Binder L, Pukrop T, Trumper L, Grimshaw MJ. Expression of endothelins and their receptors promotes an invasive phenotype of breast tumor cells but is insufficient to induce invasion in benign cells. DNA Cell Biol 2005; 24: 766-76. javascript:popRefLink(8,'rg40','16274297')
73. Wilson JL, Burchell J, Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1α. Eur J Immunol 2002; 32: 2393-00.
74. Dreau D, Karaa A, Culberson C, Wyan H, McKillop IH, Clemens MG. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis. Clin Exp Metastasis 2006; 23: 41-53.
75. Bagnato A, Rosanò L, Di Castro V, et al. Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol 2001; 158: 841-7.
76. Rosanò L, Spinella F, Di Castro V, et al. Endothelin receptor blockade inhibits molecular effectors of tumor invasion in Kaposi's sarcoma. Am J Pathol 2003; 163: 753-62.
77. Mai HQ, Zeng ZY, Zhang CQ, et al. Elevated plasma big ET-1 is associated with distant failure in patients with advanced-stage nasopharyngeal carcinoma. Cancer 2006; 106: 1548-53.
78. Wen YF, Qi B, Liu H, et al. Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma. Clin Cancer Res 2011; 17: 2451-8.
79. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406: 536-40.
80. Demunter A, De Wolf-Peeters C, Degreef H, Stas M, van den Oord JJ. Expression of the endothelin-B receptor in pigment cell lesionsof the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001; 438: 485-91.
81. Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci USA 1999; 96: 11496-00.
82. Bagnato A, Rosanò L, Spinella F, Di Castro V, Tecce R, Natali PG. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004; 64: 1436-43.
83. Bedogni B, Welford SM, Cassarino DS, Nickoloff BJ, Giaccia AJ, Powell MB. The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation. Cancer Cell 2005; 8: 443-54.
84. Lahav R, Suva ML, Rimoldi D, Patterson PH, Stamenkovic I. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res 2004; 64: 8945-53.
85. Berger Y, Bernasconi CC, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med (Maywood) 2006; 231: 1111-9.
86. Kefford R, Beith JM, Van Hazel GA, et al. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 2007; 25: 247-52.
87. Arun C, DeCatris M, Hemingway DM, London NJ, O'Byrne KJ. Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. Int J Biol Markers 2004; 19: 262-7.
88. Ahmed SI, Thompson J, Coulson JM, Woll PJ. Studies on the expression of endothelin, its receptor subtypes, and converting enzymes in lung cancer and in human bronchial epithelium. Am. J. Respir. Cell Mol Biol 2000; 22: 422-31.
89. Boldrini L, Gisfredi S, Ursino S, et al. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma. Eur J Cancer 2005; 41: 2828-35.
90. Wülfing P, Kersting C, Buerger H, et al. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer 2005; 92: 1720-8.
91. Wülfing C, Eltze E, Yamini J, et al. Expression of the endothelin axis in bladder cancer: relationship to clinicopathologic parameters and long-term survival. Eur Urol 2005;47:593-00.
92. Titus B, Frierson HF Jr, Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005; 65: 7320-27. javascript:popRefLink(8,'rg77','16103083')
93. Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. J Clin Invest 2011; 121:132-47.
94. Fisk L, Nalivaeva NN, Turner AJ. Regulation of endothelinconverting enzyme-1 expression in human neuroblastoma cells. Exp Biol Med (Maywood) 2006; 231: 1048-53.
95. Berry P, Burchill S. Endothelins may modulate invasion and proliferation of Ewing's sarcoma and neuroblastoma. Clin Sci (Lond) 2002; 103: 322S-6S.
96. Felx M, Guyot MC, Isler M, et al. Endothelin-1 (ET-1) promotes MMP-2 and MMP-9 induction involving the transcription factor NF-κB in human osteosarcoma. Clin Sci (Lond) 2006; 110: 645-54.
97. Economos K, MacDonald PC, Casey ML. Endothelin-1 gene expression and biosynthesis in human endometrial HEC-1A cancer cells. Cancer Res 1992; 52: 554-7.
98. Pekonen F, Nyman T, Ammala M, Rutanen EM. Decreased expression of messenger RNAs encoding endothelin receptors and neutral endopeptidase 24.11 in endometrial cancer. Br J Cancer 1995; 71: 59-63.
99. Suzuki T, Kikkawa F, Ino K, Nagasaka T, Tamakoshi K, Mizutani S. Imbalance between neutral endopeptidase 24.11 and endothelin-1 expression in human endometrial carcinoma. Oncology 2001; 60: 258-67.
100. Eberl LP, Valdenaire O, Saintgiorgio V, Jeannin JF, Juillerat-Jeanneret L. Endothelin receptor blockade potentiates FasLinduced apoptosis in rat colon carcinoma cells. Int J Cancer 2000; 86: 182-7.
101. Hoosein MM, Dashwood MR, Dawas K, et al. Altered endothelin receptor subtypes in colorectal cancer. Eur J Gastroenterol Hepatol 2007; 19: 775-82.
102. Knowles JP, Shiwen X, Haque SV, et al. Endothelin-1 stimulates colon cancer adjacent fibroblasts. Int J Cancer 2011; doi:10.1002/ijc.26090.
103. Kim TH, Xiong H, Zhang Z, Ren B. β-Catenin activates the growth factor endothelin-1 in colon cancer cells. Oncogene 2005; 24: 597-04.
104. Rajeshkumar NV, Rai A, Gulati A. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats. Breast Cancer Res Treat 2005; 94: 237-47.
105. Spinella F, Rosanò L, Di Castro V, et al. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Mol Cancer Ther 2006 5: 1483-92.
106. Corder R, Douthwaite JA, Lees DM, et al. Endothelin-1 synthesis reduced by red wine. Nature 2001; 414: 863-4.
107. Clozel M, Breu V, Gray GA, et al. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. J Pharmacol Exp Ther 1994; 270: 228-35.
108. Kefford RF, Clingan PR, Brady B, Ballmer A, Morganti A, Hersey P. A randomized, double-blind, placebo-controlled study of highdose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Mol Cancer 2010; 9: 69.
109. Yuyama H, Sanagi M, Koakutsu A, et al. Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ETA receptor antagonist. Eur J Pharmacol 2003; 478: 61-71.
110. Fukui R, Nishimori H, Hata F, et al. Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer 2007; 10: 123-8.
111. Yuyama H, Koakutsu A, Fujiyasu N, et al. Inhibitory effects of a selective endothelin-A receptor antagonist YM598 on endothelin-1-induced potentiation of nociception in formalin-induced and prostate cancer-induced pain models in mice. J Cardiovasc Pharmacol 2004; 44: S479-S82.
112. Yuyama H, Koakutsu A, Fujiyasu N, Tanahashi M, Fujimori A, Sato S. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain. Eur J Pharmacol 2004; 492: 177-82.
113. Battistini B, Berthiaume N, Kelland NF, Webb DJ, Kohan DE. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel '-sentan' class of drug. Exp Biol Med (Maywood) 2006; 231: 653-95.
114. Opgenorth TJ, Adler AL, Calzadilla SV, et al. Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther 1996; 276: 473-81.
115. Wu-Wong JR, Dixon DB, Chiou WJ, et al. Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: in vitro studies. Clin Sci (Lond) 2002; 103: 107S-11S.
116. Nelson JB, Chan-Tack K, Hedican SP, et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res 1996; 56: 663-8.
117. Guise TA, Yin JJ, Mohammad KS. Role of endothelin-1 in osteoblastic bone metastases. Cancer 2003; 97: 779-84.
118. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67: 3818-26.
119. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, phase II, placebo controlled trial. J Clin Oncol 2003; 21: 679-89.
120. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110: 1959-66.
121. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormonerefractory prostate cancer. Cancer 2008; 113: 2478-87.
122. Armstrong AJ, Creel P, Turnbull J, et al. A Phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008; 14: 6270-6.
123. Chiappori AA, Haura E, Rodriguez FA, et al. Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combinationwith paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008; 14: 1464-9.
124. Phuphanich S, Carson KA, Grossman SA, et al. Phase I safety study of escalating doses of atrasentan in adults with recurrent malignant glioma. Neuro Oncol 2008; 10: 617-23.
125. Manola J, Carducci M, Nair S, Liu G, Rousey S, Wilding G. Phase II ECOG trial of atrasentan in advanced renal cell carcinoma. J Clin Oncol 2007; 25: abst 5102.
126. Bradbury RH, Bath C, Butlin RJ, Dennis M, Heys C, Hunt SJ. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem 1997; 40: 996-04.
127. Morris CD, Rose A, Curwen J, Hughes AM, Wilson DJ, Webb DJ. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005; 92: 2148-52.
128. Growcott JW. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054. Anticancer Drugs 2009; 20: 83-8.
129. Curwen J, Hughes G, Hickinson M, et al. The impact of ZD4054, a specific endothelin A receptor antagonist, on tumor blood supply, invasion, and the bone microenvironment. Mol Cancer Ther 2007: 6: A272.
130. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebocontrolled, randomized, Phase II trial. Eur Urol 2009; 55: 1112-23.
131. James ND, Caty A, Payne H, et al. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial. BJU Int 2010; 106: 966-973.
132. Trump DL, Payne H, Miller K, et al. Safety and efficacy of the specific endothelin A receptor antagonist zibotentan (ZD4054) plus docetaxel in patients with metastatic hormone-resistant prostate cancer: results of a phase I study. ASCO-GU Symposium San Francisco, CA, USA, 5-7 March 2010 abst 193.
133. Nelson JB, Fizazi K, Miller K, et al. Phase III study of the efficacy and safety of zibotentan (ZD4054) in patients with bone metastatic castration-resistant prostate cancer (CRPC). ASCO-GU Symposium Orlando, FL, USA,14-19 February 2011, J Clin Oncol 2011; 29: (suppl 7; abstr 117).
134. Bagnato A, Loizidou M, Pflug BR, Curwen J, Growcott J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol 2011; 163: 220-33.